Replies to post #346048 on Innovation Pharmaceuticals Inc (IPIX)

[dreamer0]

Att, I've first hand news related to Remdesivir and Ivermectin....

Recently, I found out my whole family had Covid.
We did HR-CTS; Nasal swab; Throat swab as well...all indicated we were infected.
Parents: age>80, diabetic s, high cholesterol, heart issues etc etc.
HR-CT Scan revealed on Covid scale of 1 to 5- 2 (25%) & 4 (75+%) plus swab tests indicated Positive.

Meds used:
Mom: Remdesivir 5 shots (200mg day1 & 100mg day 2-5) plus supplemental O2

Dad: Remdesivir 5 shots (200mg day1 & 100mg day 2-5) plus supplemental O2 + Azithromycin (bid/5days), Doxycycline 100mg (bid/5days), Ivermectin 12 mg (qd/3days)

Myself: Azithromycin (bid/5days), Doxycycline 100mg (bid/5days), Ivermectin 12 mg (qd/3days)

After the treatment and we waited for one week and tested again (swab tests) plus for antibodies.

Results: Negative

Antibodies: Positive
All good as of yesterday!!!

Even with all the ailments/old age ..R worked! If there is a choice I'd go with B (imo).

[thefamilyman]

I do NOT see the need to partner for Covid. But under the scenario you propose, one of my questions would be, “Who makes the decision as to how to allocate revenue for a combo therapy?” I could see a situation where Gilead would try to give Remdesivir the lion’s share of the revenue since they would then not have to give as large of a revenue split to IPIX. If we were going to partner, I think I would prefer we do it with someone who does not have a “competing” product.

Attila said, [

i]If B's 3-in-1 only impacts Gilead's Remdesivir, then Gilead should be pursing IP if trials are deemed successful.